Check out below for data from our programs published in key scientific journals.
Clinical Autonomic Research | Published March 29, 2021
Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
Journal of Crohn’s and Colitis (JCC) | Published March 11, 2020
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme
MedRxiv | Posted March 12, 2021
A phase 2 study of the inhaled pan-JAK inhibitor TD-0903 in severe COVID-19: Part 1
Clinical Tranlational Science (CTS) | Published July 28, 2021
Phase 1 study in healthy participants to evaluate safety, tolerability and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19
YUPELRI® (revefenacin) inhalation solution | American Journal of Health-System Pharmacy (AJHP) | Published April 4, 2021
Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease
YUPELRI® (revefenacin) inhalation solution | Journal of the COPD Foundation (JCOPDF) | Published March 13, 2020
Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day Study
YUPELRI® (revefenacin) inhalation solution | Journal of the COPD Foundation (JCOPDF) | Published September 23, 2019
Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients with COPD and Suboptimal Peak Inspiratory Flow Rate
